Compare Home Depot Inc (HD) vs TG Therapeutics Inc (TGTX) Price & Performance

Home Depot (HD) trades at $344.63, down 1.75% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue grew to $159.51 billion in 2025, though net margins have declined to 8.41%. The stock benefits from strong analyst support, with a consensus price target of $371.25, and a dividend payment scheduled for June 2026.

The stock presents a long-term opportunity driven by Pro customer growth and housing tailwinds, but faces risks from weakening big-ticket demand and margin pressures. With 59% of analysts rating it a buy, upside exists if earnings rebound, though high valuation multiples and economic sensitivity warrant caution.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.